CB2 receptors as new therapeutic targets for liver diseases
about
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilitiesIs lipid signaling through cannabinoid 2 receptors part of a protective system?Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assayThe role of endocannabinoids system in fatty liver disease and therapeutic potentialsCannabinoid receptor with an 'identity crisis' gets a second lookCannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosisEndocannabinoid receptors gene expression in morbidly obese women with nonalcoholic fatty liver disease.Targeting cannabinoid signaling for peritoneal dialysis-induced oxidative stress and fibrosis.CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model.CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?Endocannabinoids in liver disease.Unique pathway for anandamide synthesis and liver regenerationThe endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openingsProtective role of cannabinoid receptor 2 activation in galactosamine/lipopolysaccharide-induced acute liver failure through regulation of macrophage polarization and microRNAs.Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments.A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injuryExcess of the endocannabinoid anandamide during lactation induces overweight, fat accumulation and insulin resistance in adult mice.Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor.Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: implications for atherosclerosis and inflammatory diseases.Modulating the endocannabinoid system in human health and disease--successes and failuresCannabinoid receptor CB2 protects against balloon-induced neointima formation.Emerging strategies for exploiting cannabinoid receptor agonists as medicines.Capsaicin affects brain function in a model of hepatic encephalopathy associated with fulminant hepatic failure in mice.The effect of endocannabinoid system in ischemia-reperfusion injury: a friend or a foe?The peripheral cannabinoid receptor 1 antagonist VD60 efficiently inhibits carbon tetrachloride-intoxicated hepatic fibrosis progression.Cannabinoid receptors as therapeutic targets for dialysis-induced peritoneal fibrosis.β-Caryophyllene attenuates palmitate-induced lipid accumulation through AMPK signaling by activating CB2 receptor in human HepG2 hepatocytes.Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration.Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice.Anti-inflammatory cannabinoids in diet: Towards a better understanding of CB(2) receptor action?CB2 cannabinoid receptors: new vistas.Endocannabinoid-related compounds in gastrointestinal diseases.Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease.
P2860
Q24623282-05E5DF8F-1697-476C-99D8-4D85CD9E45DDQ24633122-58355F8D-0DAB-4EA3-B7B7-68E212DD41BAQ24654730-54988F68-93D3-4B9C-9CA5-DD295C65F4C4Q27009466-EF57919F-FBC7-4F49-B942-3D6793EA2990Q29397935-62E7913B-14C5-4E8E-96F7-ACB95CD701A2Q33464957-56BDA09F-28F6-46A8-8FFE-5B9FAD06FA00Q33597839-48A7E837-B5EC-43A0-8F0C-C777F5F8C273Q33655394-CB8129B2-A377-40C8-8C79-450DEFE2B441Q34098258-22B1D586-0AB0-4391-8E48-B8397CB4C084Q34186015-592398C2-A001-4709-8C39-96E44DA3E205Q34776919-33943230-26A0-44C4-B432-1705DD205C97Q34835434-C4C8A382-E400-431B-A336-5B81986E2353Q35193292-9C66DEE3-A151-4D09-857B-5B1D7596C4B4Q35531807-D011332B-80E0-4FF4-AE0D-C3F0015D5465Q36026554-28BFD7B7-B442-4B6D-9E13-940A64035546Q36176499-CCF73A8B-6E25-461D-9822-2F33DAF51921Q36226578-AF54C96F-08BB-4728-A7CC-E705CB430887Q36242609-8BA7ED0A-61B2-4E7A-B840-B5184A8CD55FQ36496316-B793B301-34BB-46E6-AFCA-8211CDC24229Q36933683-F44D8469-F8AF-414D-B442-0BB6ACEE36F5Q37174735-92D57A3E-0402-4BFE-9327-62CFCF3B524DQ37230665-52838B8A-14C3-421D-B26A-E9C3B9665A61Q37395929-9AF80E1F-666F-45FC-98DB-A1D80B4B7148Q38455748-B64603A5-4119-410E-8321-1EF0AB0259DFQ39031169-CAD42869-E2F3-475E-94B2-A474C5F30C03Q39215034-21D95D28-856C-408F-8AEB-F309CB4B034AQ39730050-70064718-B87C-4F4E-A77D-ACB5346DA21CQ40001901-997B7EA5-2D57-49A8-969B-0B3A1C129756Q41855701-3A1D381B-8629-4E57-ABE1-7CA2DC128C6FQ43190361-871D6E9B-19F5-49F4-BBE0-A3E2499C46B2Q45854330-62411356-C686-4ED4-861F-4B3846516022Q47839554-9021B6B8-3492-4589-B97E-831B5BFB77A4Q55452630-42EE8725-3E67-4E20-8694-EBFCD844463C
P2860
CB2 receptors as new therapeutic targets for liver diseases
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
CB2 receptors as new therapeutic targets for liver diseases
@en
type
label
CB2 receptors as new therapeutic targets for liver diseases
@en
prefLabel
CB2 receptors as new therapeutic targets for liver diseases
@en
P2093
P2860
P356
P1476
CB2 receptors as new therapeutic targets for liver diseases
@en
P2093
F Teixeira-Clerc
J Tran-Van-Nhieu
S Lotersztajn
Y Ichigotani
P2860
P304
P356
10.1038/SJ.BJP.0707511
P407
P577
2007-10-22T00:00:00Z